Stanford, CA – October 30, 2026 – Starton Therapeutics has announced a significant collaboration with the prestigious Stanford School of Medicine to initiate a crucial investigator-initiated clinical trial. This groundbreaking study will evaluate the safety and efficacy of Starton’s novel continuous-delivery lenalidomide candidate, STAR-LLD, when combined with a new chimeric antigen receptor (CAR) T-cell therapy in patients battling relapsed or refractory multiple myeloma (MM). The agreement underscores a shared commitment to advancing innovative cancer treatments and addressing unmet needs in hematological malignancies.
Under the terms of the agreement, Stanford Medicine will assume complete responsibility for the meticulous design of the clinical protocol and the rigorous execution of the trial. This includes patient recruitment, data collection, and the comprehensive analysis of trial outcomes. The collaboration leverages Stanford’s renowned expertise in clinical research and CAR T-cell therapy, positioning the trial for robust scientific inquiry and the generation of high-quality data.
Main Facts: A Novel Combination for Relapsed/Refractory Multiple Myeloma
The upcoming clinical trial will focus on a critical patient population: individuals diagnosed with relapsed or refractory multiple myeloma. This aggressive form of blood cancer is characterized by its resistance to conventional treatments and often presents significant challenges for clinicians and patients alike. The investigational regimen aims to provide a new therapeutic avenue by combining the sustained release of lenalidomide, delivered via STAR-LLD, with the targeted power of CAR T-cell therapy.
The primary objectives of this investigator-initiated trial are to comprehensively assess the safety profile of the combined treatment approach and to identify early signals of efficacy. Researchers will meticulously monitor for any adverse events and evaluate the potential for improved clinical outcomes in patients who have historically struggled to achieve durable remissions.
Beyond safety and efficacy, the study will delve into the intricate immunological mechanisms underpinning the combination therapy. A key component of the trial will involve the measurement of correlative biomarkers. This detailed analysis will aim to map immune responses across various dosage levels of STAR-LLD and to establish clear pharmacokinetic and pharmacodynamic relationships. Understanding these interactions is vital for optimizing the therapeutic strategy and predicting patient responses. Specifically, researchers will investigate whether the co-administration of STAR-LLD with cellular immunotherapies, such as CAR T-cells, leads to enhanced therapeutic outcomes. This exploration into synergistic effects could unlock new paradigms in cancer treatment.
Chronology: A Strategic Advancement in Cancer Therapy Development
The announcement of this clinical trial marks a pivotal moment in Starton Therapeutics’ development pipeline. The company has strategically positioned STAR-LLD as a platform technology designed to enhance the tolerability and efficacy of approved cancer therapies through continuous delivery systems. This collaboration with Stanford Medicine is a critical step towards realizing the full potential of STAR-LLD in the complex landscape of multiple myeloma treatment.
Starton Therapeutics intends to leverage the data generated from this trial to support an Investigational New Drug (IND) application. This application will pave the way for a subsequent Phase II trial, which is envisioned to further evaluate the combination of STAR-LLD with B-cell maturation antigen (BCMA) CAR-T therapies in patients with multiple myeloma. BCMA is a well-established target for CAR T-cell therapy in MM, and combining it with a novel lenalidomide delivery system represents a promising approach to overcome treatment resistance and improve patient outcomes.
This strategic progression from an investigator-initiated trial to a potential larger-scale Phase II study highlights the company’s commitment to a data-driven development strategy. The successful execution of this initial trial will provide crucial insights that will inform future clinical development and regulatory submissions.
Supporting Data: Promising Preclinical and Early Clinical Insights
Starton Therapeutics’ STAR-LLD is an innovative formulation of lenalidomide designed for continuous delivery. Lenalidomide, a well-established immunomodulatory drug, has been a cornerstone in the treatment of multiple myeloma and chronic lymphocytic leukemia. However, its oral administration can lead to fluctuating drug levels and potential dose-limiting toxicities. STAR-LLD aims to overcome these limitations by providing a consistent and sustained release of the drug, potentially improving patient compliance and tolerability.
The development of STAR-LLD is supported by compelling preclinical data and promising early-phase clinical results. In prior Phase Ib clinical testing, STAR-LLD was administered to six individuals diagnosed with relapsed or refractory multiple myeloma. The results from this initial study were highly encouraging, with all participants demonstrating objective responses. This included one complete response (CR) and five partial responses (PR), indicating a significant clinical benefit in this heavily pre-treated patient population.
Furthermore, the safety profile observed in this Phase Ib study was particularly noteworthy. Across treatment courses lasting up to 12 cycles, none of the subjects experienced treatment-related anemia, leukopenia, neutropenia, or thrombocytopenia exceeding Grade 2. This suggests that the continuous delivery of lenalidomide via STAR-LLD may significantly mitigate some of the common hematological toxicities associated with conventional oral lenalidomide, thereby improving the patient’s quality of life during treatment.
Starton Therapeutics’ broader mission is to develop continuous-delivery systems that can adapt existing cancer therapies, enhance their tolerability, and expand their therapeutic applications. This includes leveraging innovative delivery technologies. Notably, in September 2024, the company successfully demonstrated the use of BD’s on-body injector technology for the delivery of STAR-LLD. This achievement highlights Starton’s commitment to exploring advanced drug delivery mechanisms to optimize cancer treatment.
Official Responses: A Vision for Improved Patient Outcomes
The collaboration between Starton Therapeutics and Stanford Medicine has been met with enthusiasm from key stakeholders. Pedro Lichtinger, Chairman and CEO of Starton Therapeutics, expressed his excitement about the partnership and the potential of STAR-LLD.
“We are excited to collaborate with Stanford Medicine and advance the evaluation of STAR-LLD,” Lichtinger stated. “This agreement represents an important step in our strategy, as we believe this combination has the potential to improve CAR-T cell expansion and persistence, while minimizing the known toxicity of immunomodulatory imide drugs (IMiD).”
Lichtinger’s statement underscores the strategic rationale behind combining STAR-LLD with CAR T-cell therapy. CAR T-cell therapies, while highly effective, can sometimes suffer from limited persistence or expansion in the tumor microenvironment. The sustained release of lenalidomide from STAR-LLD may offer immunomodulatory benefits that could enhance the engraftment, proliferation, and sustained activity of CAR T-cells. Moreover, by potentially reducing the need for higher doses of oral IMiDs, STAR-LLD could mitigate the associated toxicities, leading to a more tolerable and effective treatment regimen for patients.
The involvement of Stanford Medicine, a leading institution in cancer research and cellular therapy, lends significant credibility to the trial. The investigator-initiated nature of the study further signifies the scientific merit and potential impact of the proposed research, as it originates from the researchers’ keen interest and expertise in addressing critical unmet needs in multiple myeloma.
Implications: Redefining Treatment Paradigms for Multiple Myeloma
The implications of this collaboration and the potential success of the STAR-LLD and CAR T-cell combination are far-reaching for the field of multiple myeloma treatment.
Firstly, if the trial demonstrates improved safety and efficacy, it could pave the way for a new standard of care for patients with relapsed or refractory MM. The current treatment landscape for these patients often involves sequential lines of therapy with varying degrees of success and significant toxicity. A combination therapy that offers enhanced efficacy with improved tolerability would be a significant advancement.
Secondly, the study’s focus on understanding the immunological interplay between STAR-LLD and CAR T-cells could yield critical insights into the mechanisms of action for combination therapies in hematological malignancies. This knowledge could inform the development of similar strategies for other cancers and guide the design of future clinical trials.
Thirdly, the successful development of STAR-LLD as a continuous-delivery system could have broader implications for the delivery of other lenalidomide-based therapies and potentially other immunomodulatory drugs. By improving tolerability and simplifying administration, such systems can enhance patient adherence and ultimately improve treatment outcomes.
Finally, this collaboration exemplifies the power of academic-industry partnerships in accelerating the translation of innovative scientific discoveries into tangible patient benefits. The synergistic strengths of Stanford Medicine’s research prowess and Starton Therapeutics’ novel drug delivery platform have the potential to create a significant impact on the lives of individuals battling multiple myeloma. The upcoming trial represents a beacon of hope and a testament to the ongoing pursuit of more effective and patient-centric cancer therapies.
About the Author
